Starting July 1, 2026, Medicare’s GLP‑1 Bridge will let select Part D enrollees get Wegovy, Zepbound or Foundayo for $50 a month — but strict BMI and health rules apply.

A University of Georgia meta‑analysis found tirzepatide produced the largest weight loss among GLP‑1 therapies in non‑diabetic adults, but questions remain on durability and access.

UNLV researchers were among co‑authors of a GBD study published in Med that finds the U.S. had the highest substance use disorder prevalence in 2023 and projects increases to 2050 without intervention.